Samuel Bates Martin Celldex Therapeutics, Inc. (CLDX) insider trading activity

Samuel Bates Martin is SVP AND CFO of Celldex Therapeutics, Inc.. Currently has a direct ownership of 28,125 shares of CLDX, which is worth approximately $1.24 Million. The most recent transaction as insider was on Jun 14, 2024, when has been sold 17,172 shares (Common Stock) at a price of $35.42 per share, resulting in proceeds of $608,232. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 28.1K

0% 3M change

15.37% 12M change

Total Value Held $1.24 Million

Samuel Bates Martin Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 14 2024	SELL Open market or private sale	$608,232 $35.42 p/Share	17,172 Reduced 37.91%	28,125 Common Stock
Jun 14 2024	BUY Exercise of conversion of derivative security	$195,639 $9.7 p/Share	20,169 Added 30.81%	45,297 Common Stock
May 30 2024	SELL Open market or private sale	$1,191,750 $34.05 p/Share	35,000 Reduced 58.21%	25,128 Common Stock
May 30 2024	BUY Exercise of conversion of derivative security	$259,500 $10.38 p/Share	25,000 Added 29.37%	60,128 Common Stock
Jan 02 2024	BUY Exercise of conversion of derivative security	$29,884 $2.78 p/Share	10,750 Added 23.43%	35,128 Common Stock
Aug 12 2022	SELL Open market or private sale	$624,498 $35.59 p/Share	17,547 Reduced 41.85%	24,378 Common Stock
Aug 12 2022	BUY Exercise of conversion of derivative security	$103,527 $5.9 p/Share	17,547 Added 29.5%	41,925 Common Stock
Aug 11 2022	SELL Open market or private sale	$90,859 $37.04 p/Share	2,453 Reduced 9.14%	24,378 Common Stock
Aug 11 2022	BUY Exercise of conversion of derivative security	$22,126 $9.02 p/Share	2,453 Added 8.38%	26,831 Common Stock
Dec 23 2021	SELL Open market or private sale	$399,000 $42.0 p/Share	9,500 Reduced 28.04%	24,378 Common Stock
Dec 23 2021	BUY Exercise of conversion of derivative security	$41,300 $5.9 p/Share	7,000 Added 17.12%	33,878 Common Stock
Nov 15 2021	SELL Open market or private sale	$409,355 $43.09 p/Share	9,500 Reduced 26.11%	26,878 Common Stock
Nov 15 2021	BUY Exercise of conversion of derivative security	$41,300 $5.9 p/Share	7,000 Added 16.14%	36,378 Common Stock
Aug 10 2021	SELL Open market or private sale	$123,894 $45.25 p/Share	2,738 Reduced 8.53%	29,378 Common Stock
Aug 10 2021	BUY Exercise of conversion of derivative security	$126,148 $5.9 p/Share	21,381 Added 41.56%	30,060 Common Stock

SBM

Samuel Bates Martin

SVP AND CFO

Hampton, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CLDX shares.

Notify only if

Value

Insider Trading

Get notified when an Celldex Therapeutics, Inc. insider buys or sells CLDX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Celldex Therapeutics, Inc.

Track Activities on CLDX

Account